Immunomedics (IMMU) Leaps on Positive Results

Immunomedics, Inc. IMMU shares rose 17.2% to $2.52 following the announcement of interim Phase 2 Results with sacituzumab govitecan in lung cancers. Share volume was 170,000, compared to an all-day average of 297,000